Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J S Bevan

Showing results (11-20 of 67) with videos related to

Pageof 7
Sort By:
Clinical Endocrinology|June 1, 1989
Perifusion studies of bromocriptine-treated and untreated macroprolactinomas: effects of dopamine, bromocriptine and TRHJ S Bevan, C W Burke
Clinical Endocrinology|December 1, 1994
Cabergoline: an advance in dopaminergic therapyJ S Bevan, J R Davis
Clinical Endocrinology|November 1, 1986
Non-functioning pituitary adenomas do not regress during bromocriptine therapy but possess membrane-bound dopamine receptors which bind bromocriptineJ S Bevan, C W Burke
Annals of Clinical Biochemistry|November 1, 1986
Sensitive and specific bromocriptine radioimmunoassay with iodine label: measurement of bromocriptine in human plasmaJ S Bevan, D Baldwin, C W Burke
The British Journal of Clinical Practice|January 1, 1992
Quinine-induced cutaneous vasculitisE J Price, J S Bevan, A Rees
Age and Ageing|July 1, 1989
The presentation and management of pituitary tumours in the elderlyD L Cohen, J S Bevan, C B Adams
AIDS Care|December 16, 2015
Age and injecting drug use revisited: the Australian Study of HIV and Injecting Drug UseW M Loxley, J S Bevan, S J Carruthers
Clinical Endocrinology|March 1, 1996
Structure of the thyrotrophin-releasing hormone receptor in human pituitary adenomasE Faccenda, S Melmed, J S Bevan, et al.
Trends in Endocrinology and Metabolism: TEM|November 1, 1989
Growth factors and pituitary tumorsJ Webster, J Ham, J S Bevan, et al.
Drug and Alcohol Review|October 6, 2005
The Australian Study of HIV and Injecting Drug Use. Part I: prevalence for HIV, hepatitis B and hepatitis C among injecting drug users in four Australian citiesW M Loxley, M Phillips, S J Carruthers, et al.
Pageof 7

Showing results (11-20 of 67) with videos related to

Sort By:
Pageof 7
Clinical Endocrinology|June 1, 1989
Perifusion studies of bromocriptine-treated and untreated macroprolactinomas: effects of dopamine, bromocriptine and TRHJ S Bevan, C W Burke
Clinical Endocrinology|December 1, 1994
Cabergoline: an advance in dopaminergic therapyJ S Bevan, J R Davis
Clinical Endocrinology|November 1, 1986
Non-functioning pituitary adenomas do not regress during bromocriptine therapy but possess membrane-bound dopamine receptors which bind bromocriptineJ S Bevan, C W Burke
Annals of Clinical Biochemistry|November 1, 1986
Sensitive and specific bromocriptine radioimmunoassay with iodine label: measurement of bromocriptine in human plasmaJ S Bevan, D Baldwin, C W Burke
The British Journal of Clinical Practice|January 1, 1992
Quinine-induced cutaneous vasculitisE J Price, J S Bevan, A Rees
Age and Ageing|July 1, 1989
The presentation and management of pituitary tumours in the elderlyD L Cohen, J S Bevan, C B Adams
AIDS Care|December 16, 2015
Age and injecting drug use revisited: the Australian Study of HIV and Injecting Drug UseW M Loxley, J S Bevan, S J Carruthers
Clinical Endocrinology|March 1, 1996
Structure of the thyrotrophin-releasing hormone receptor in human pituitary adenomasE Faccenda, S Melmed, J S Bevan, et al.
Trends in Endocrinology and Metabolism: TEM|November 1, 1989
Growth factors and pituitary tumorsJ Webster, J Ham, J S Bevan, et al.
Drug and Alcohol Review|October 6, 2005
The Australian Study of HIV and Injecting Drug Use. Part I: prevalence for HIV, hepatitis B and hepatitis C among injecting drug users in four Australian citiesW M Loxley, M Phillips, S J Carruthers, et al.
Pageof 7